Preoperative plasma level of endoglin as a predictor for disease outcomes after radical cystectomy for nonmetastatic urothelial carcinoma of the bladder
Authors:
- Ekaterina LaukhtinaELEkaterina Laukhtina
- Victor M. SchuettfortVSVictor M. Schuettfort
- David D'AndreaDDDavid D'Andrea
- Benjamin PradereBenjamin Pradere
- Keiichiro MoriKMKeiichiro Mori
- Fahad QuhalFQFahad Quhal
- Reza Sari MotlaghRMReza Sari Motlagh
- Hadi MostafaeiHMHadi Mostafaei
- Satoshi KatayamaSKSatoshi Katayama
- Nico С. GrossmannNGNico С. Grossmann
- Pawel RajwaPRPawel Rajwa
Open Access
- 29 September 2021
- journal article
- research article
- Published by Wiley in Molecular Carcinogenesis
- Vol. 61 (1) , 5-18
Abstract
Elevated preoperative plasma level of endoglin has been associated with worse oncologic outcomes in various malignancies. The present large-scale study aimed to determine the predictive and prognostic values of preoperative endoglin with regard to clinicopathologic and survival outcomes in patients treated with radical cystectomy (RC) for nonmetastatic urothelial carcinoma of the bladder (UCB). We prospectively collected preoperative blood samples from 1036 consecutive patients treated with RC for UCB. Logistic and Cox regression analyses were undertaken to assess the correlation of endoglin levels with pathologic and survival outcomes, respectively. The AUC and C-index were used to assess the discrimination. Patients with adverse pathologic features had significantly higher median preoperative endoglin plasma levels than their counterparts. Higher preoperative endoglin level was independently associated with an increased risk for lymph node metastasis, ≥pT3 disease, and nonorgan confined disease (NOCD; all p < 0.001). Plasma endoglin level was also independently associated with cancer-specific and overall survival in both pre- and postoperative models (all p < 0.05), as well as with recurrence-free survival (RFS) in the preoperative model (p < 0.001). The addition of endoglin to the preoperative standard model improved its discrimination for prediction of lymph node metastasis, ≥pT3 disease, NOCD, and RFS (differential increases in C-indices: 10%, 5%, 5.8%, and 4%, respectively). Preoperative plasma endoglin is associated with features of biologically and clinically aggressive UCB as well as survival outcomes. Therefore, it seems to hold the potential of identifying UCB patients who may benefit from intensified therapy in addition to RC such as extended lymphadenectomy or/and preoperative systemic therapy.Keywords
This publication has 43 references indexed in Scilit:
- Metabolomic Profiling Reveals Potential Markers and Bioprocesses Altered in Bladder Cancer ProgressionCancer Research, 2011
- Tumor markers in prostate cancer I: Blood-based markersActa Oncologica, 2011
- Statistical consideration for clinical biomarker research in bladder cancerUrologic Oncology: Seminars and Original Investigations, 2010
- Prechemotherapy Serum Levels of CD105, Transforming Growth Factor β2, and Vascular Endothelial Growth Factor Are Associated With Prognosis in Patients With Advanced Epithelial Ovarian Cancer Treated With Cytoreductive Surgery and Platinum-Based ChemotherapyInternational Journal of Gynecological Cancer, 2010
- Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressivenessLaboratory Investigation, 2007
- Survivin expression is associated with bladder cancer presence, stage, progression, and mortalityCancer, 2007
- Precystectomy Nomogram for Prediction of Advanced Bladder Cancer StageEuropean Urology, 2006
- Lymphovascular Invasion is a Pathological Feature of Biologically Aggressive Disease in Patients Treated With Radical ProstatectomyJournal of Urology, 2004
- E-CADHERIN IMMUNOSTAINING OF BLADDER TRANSITIONAL CELL CARCINOMA, CARCINOMA IN SITU AND LYMPH NODE METASTASES WITH LONG-TERM FOLLOWUPJournal of Urology, 2001
- What Is the Evidence That Tumors Are Angiogenesis Dependent?JNCI: Journal of the National Cancer Institute, 1990